Skip to content
Open access

High-impact medicines, system sustainability and the role of access management: evidence from Catalonia

Oct 2026 · Health Policy OPEN · Vol 11, pp. 100189 · 0 citations · 26 references
Medicine

TL;DR

These findings illustrate how the broad use of managed access mechanisms can support balancing access to innovation with health system sustainability, and identify the most effective managed access strategies to facilitate access to new HIMs at costs sustainable for health systems.

Abstract

Background The reimbursement of high-impact medicines (HIMs) poses growing clinical and budgetary challenges for publicly funded health systems. In Catalonia, pharmaceutical spending has increased considerably in recent years, driven by the uptake of high-cost therapies and expanded indications under clinical and economic uncertainty. To mitigate these risks, payers have increasingly used managed access mechanisms in reimbursement strategies. Objective To assess the economic impact of newly reimbursed high-impact medicines in Catalonia and describe the role and economic implications of managed access mechanisms applied to address clinical and financial uncertainty. Methods We conducted a retrospective study using real-world data from Catalonia's health service registries and billing systems. Expenditure trends for HIMs between 2019 and 2024 were analysed. Newly reimbursed indications from 2022 to 2024 were evaluated by therapeutic class, volume of patients, and aggregated expenditure per patient, taking into account the managed access mechanisms applied. Results From 2019 to 2024, HIM expenditure rose by 53% in nominal terms, from €1.10 billion to €1.69 billion; after adjustment for inflation, 2019 expenditure corresponded to approximately €1.30 billion in 2024 euros, indicating a real increase of approximately 30%. In 2024, HIM expenditure represented about 11% of the total healthcare expenditure managed by the Catalan Health Service. The top 10 medicines accounted for 43% of expenditure. Newly reimbursed indications in 2024 represented €23.6 million. Managed access mechanisms were applied to nearly three-quarters of these indications, including indication-based restrictions and formal agreements. Formal managed access agreements included confidential discounts, spending caps, patient-level spending caps, free-dose schemes, price–volume agreements, outcome-based payment models, and staggered payments. Conclusions Newly reimbursed HIMs exert concentrated expenditure pressure. These findings illustrate how the broad use of managed access mechanisms can support balancing access to innovation with health system sustainability. Future research is needed to identify the most effective managed access strategies to facilitate access to new HIMs at costs sustainable for health systems.

Read PDF

Similar papers

Review Open access Oct 2026

[Translated article] Farmastock: A collaborative tool for the reuse of high-cost hospital medications in a public healthcare system.

BACKGROUND The loss of high-cost hospital medicines due to expiration represents a structural problem affecting the efficiency and sustainability of the public healthcare system. This loss is not solely the result of management inefficiencies; it is frequently driven by unpredictable changes in patient clinical evoluti...

M. Gallego-Galisteo, Javier Romero-Puerto, M. L. López-Mancha et al. · 0 citations
Review Open access Sep 2026

A model for the clinical management of the introduction of new medicines in a large University Hospital in Spain

ABSTRACT Background New medicines offer therapeutic opportunities but also challenge healthcare system organisation and sustainability. This study aims to describe a model based on regular multidisciplinary meetings to manage and monitor the introduction of new medicines for Hospital Outpatient Treatments (HOT) in a Sp...

I. Danés, A. Agustí, E. Ballarín et al. · 0 citations
Editorial Oct 2026

Value-based care contracting for pharmacy drugs: opportunity for the United States.

This analysis presents a path forward for the expansion of VBC to promote orphan drug development, expand access to pharmaceuticals, and improve patient safety and explores different contracting options and paths for organizations like CMS and integrated payer-provider networks.

Urvisha Jain, Srinidhi Polkampally, Arnav Ajay Jadav et al. · 0 citations
Review Open access Oct 2026

Beyond Financial Health: Community Pharmacy Sustainability and Access to Affordable Medicines

Community pharmacies must remain financially viable without weakening access to affordable medicines. This public commentary examines Panga and Galvez's survey of financial sustainability practices among small and medium-scale pharmacies in Naga City. The study provides useful local evidence on cost optimization, custo...

Aliana V. Gomez · 0 citations
Review Open access Oct 2026

Evaluation of high-technology medicines considering budget impact and societal value: a three-tier approach using incretin-based therapy as an example

Objective: To develop a three-tier approach to assessing the value of high-technology medicines, provide a rationale for the approach, and demonstrate its applicability using incretin-based therapy as an example. Material and methods. A conceptual study was carried out using a descriptive analysis...

А. А. Lee, D. О. Borisov, V. S. Novikova et al. · 0 citations
Review Open access Nov 2026

The impact of centralized drug purchasing policy on pediatric medicines and related health system performance outcomes: a systematic review and evidence gap map

Centralized drug purchasing policies have been applied in many countries, but the impact on pediatric medicine supply has been controversial. In this study, we evaluated the impact of centralized drug purchasing policies on pediatric medicines and related health system performance outcomes. Eight databases,...

Lu Han, Jia-Ning Liu, Hai-Long Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.